Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

we believe that the list of agents previously considered first- and second-line medications for the overactive bladder needs to be revised. State-of-the-art treatment of OAB in 1999 includes ...

(HealthDay News) — Gemtesa (vibegron) has been approved by the US Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ... who are receiving ...

2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ... who are ...